All In MedTech

Device Trial Radar · NCT03944525

High-flow Air Via Nasal Cannula vs Non-invasive Continuous Positive Airway Pressure for Hypercapnic Respiratory Failure

High-flow Air Via Nasal Cannula Versus Non-invasive Continuous Positive Airway Pressure Ventilation Support for Hypercapnic Respiratory Failure The HIGH-for-HYPER Study

Last checked: Nov 20, 2026Latest source record: Feb 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

62

Planned (sponsor's estimate)

Start

Jan 1, 2020

Primary completion

Dec 31, 2020

Study completion Jun 30, 2021

Sponsor

Lead sponsor
Medical University of ViennaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 9, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will be performed as a randomized controlled non-inferiority trial. HFA has been increasingly used in the last years to treat hypoxic respiratory failure (i.e. type I failure), and numerous studies have shown its efficiency in this indication. Despite this good evidence for HFA in hypoxic respiratory failure, it has only reluctantly been used for hypercapnic respiratory failure. HFA has been shown to generate PEEP, despite not being a closed system, and to improve CO2 clearance by flushing anatomical dead space. It might also help to reduce inspiratory resistance and facilitate secretion clearance from humidified gas. A study on COPD patients showed an increase in breathing pressure amplitude and mean pressure, as well as tidal volume, with a trend towards reduction of carbon dioxide partial pressure. Intervention consists of HFA using standard equipment at the department. A gas flow of 60 litres per minute and a FiO2 as clinically feasible will be used. Therapy will be continued until a pCO2-level of 50 mmHg or less is reached, or therapy has to be aborted because of lack of tolerance by the patient or indication for intubation. Control consists of non-invasive continuous positive airway pressure ventilation support using a tight mask and standard respirator equipment of the Department of Emergency Medicine. A positive airway pressure of 3,67 mmHg and a FiO2 as clinically feasible will be used. Therapy will be continued until a pCO2-level of 50 mmHg or less is reached, or therapy has to be aborted because of lack of tolerance by the patient or indication for intubation.

Conditions

  • Hypercapnic Respiratory Failure

Interventions

  • High flow nasal cannulaDevice

    Oxygen-therapy via HFNC

  • Continuous positive airway pressureDevice

    Non-invasive CPAP ventilation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of pCO2 in arterial blood gasTime frame: first 24 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical University Vienna

    Vienna, Austria · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.